Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 406

1.

Validation of a Software Upgrade in a Monte Carlo Treatment Planning System by Comparison of Plans in Different Versions.

Mohandass P, Khanna D, Manigandan D, Bhalla NK, Puri A.

J Med Phys. 2018 Apr-Jun;43(2):93-99. doi: 10.4103/jmp.JMP_7_18.

2.

NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension.

Samokhin AO, Stephens T, Wertheim BM, Wang RS, Vargas SO, Yung LM, Cao M, Brown M, Arons E, Dieffenbach PB, Fewell JG, Matar M, Bowman FP, Haley KJ, Alba GA, Marino SM, Kumar R, Rosas IO, Waxman AB, Oldham WM, Khanna D, Graham BB, Seo S, Gladyshev VN, Yu PB, Fredenburgh LE, Loscalzo J, Leopold JA, Maron BA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaap7294. doi: 10.1126/scitranslmed.aap7294.

PMID:
29899023
3.

Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.

Khanna D, Tashkin DP, Denton CP, Lubell MW, Vazquez-Mateo C, Wax S.

Rheumatology (Oxford). 2018 Jun 8. doi: 10.1093/rheumatology/key151. [Epub ahead of print]

PMID:
29893938
4.

Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.

Stifano G, Sornasse T, Rice LM, Na L, Chen-Harris H, Khanna D, Jahreis A, Zhang Y, Siegel J, Lafyatis R.

Arthritis Rheumatol. 2018 Jun;70(6):912-919. doi: 10.1002/art.40455.

PMID:
29858547
5.

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.

Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, Khanna D, Jahreis A, Siegel J, Sornasse T.

Ann Rheum Dis. 2018 Sep;77(9):1362-1371. doi: 10.1136/annrheumdis-2018-213031. Epub 2018 May 31.

6.

Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts.

He Y, Tsou PS, Khanna D, Sawalha AH.

Ann Rheum Dis. 2018 Aug;77(8):1208-1218. doi: 10.1136/annrheumdis-2018-213022. Epub 2018 May 14.

PMID:
29760157
7.

A Randomized Controlled Trial to Evaluate an Internet-Based Self-Management Program in Systemic Sclerosis.

Khanna D, Serrano J, Berrocal VJ, Silver RM, Cuencas P, Newbill SL, Battyany J, Maxwell C, Alore M, Dyas L, Riggs R, Connolly K, Kellner S, Fisher JJ, Bush E, Sachdeva A, Evnin L, Raisch DW, Poole JL.

Arthritis Care Res (Hoboken). 2018 May 9. doi: 10.1002/acr.23595. [Epub ahead of print]

PMID:
29741230
8.

Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study.

Allanore Y, Distler O, Jagerschmidt A, Illiano S, Ledein L, Boitier E, Agueusop I, Denton CP, Khanna D.

Arthritis Rheumatol. 2017 Aug 12. doi: 10.1002/art.40547. [Epub ahead of print]

9.

Whole-Exome Sequencing to Identify Rare Variants and Gene Networks that Increase Susceptibility to Scleroderma in African Americans.

Gourh P, Remmers EF, Boyden SE, Alexander T, Morgan ND, Shah AA, Mayes MD, Doumatey A, Bentley AR, Shriner D, Domsic RT, Medsger TA Jr, Steen VD, Ramos PS, Silver RM, Korman B, Varga J, Schiopu E, Khanna D, Hsu V, Gordon JK, Saketkoo LA, Gladue H, Kron B, Criswell LA, Derk CT, Bridges SL Jr, Shanmugam VK, Kolstad KD, Chung L, Jan R, Bernstein EJ, Goldberg A, Trojanowski M, Kafaja S, Maksimowicz-McKinnon KM, Mullikin JC; NISC Comparative Sequencing Program, Adeyemo A, Rotimi C, Boin F, Kastner DL, Wigley FM.

Arthritis Rheumatol. 2018 May 6. doi: 10.1002/art.40541. [Epub ahead of print]

PMID:
29732714
10.

pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis.

Kafaja S, Valera I, Divekar AA, Saggar R, Abtin F, Furst DE, Khanna D, Singh RR.

JCI Insight. 2018 May 3;3(9). pii: 98380. doi: 10.1172/jci.insight.98380. [Epub ahead of print]

11.

Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.

Ingegnoli F, Schioppo T, Allanore Y, Caporali R, Colaci M, Distler O, Furst DE, Hunzelmann N, Iannone F, Khanna D, Matucci-Cerinic M.

Semin Arthritis Rheum. 2018 Apr 4. pii: S0049-0172(18)30013-1. doi: 10.1016/j.semarthrit.2018.03.019. [Epub ahead of print] Review.

PMID:
29706243
12.

Leonine facies presenting as scleromyxedema.

Park AY, Lowe L, Khanna D.

Arthritis Rheumatol. 2018 Apr 20. doi: 10.1002/art.40530. [Epub ahead of print]

PMID:
29676525
13.

The patient experience of Raynaud's phenomenon in systemic sclerosis.

Pauling JD, Saketkoo LA, Matucci-Cerinic M, Ingegnoli F, Khanna D.

Rheumatology (Oxford). 2018 Mar 12. doi: 10.1093/rheumatology/key026. [Epub ahead of print]

PMID:
29538754
14.

Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis.

Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H, Frech TM, Ingegnoli F, Dures E, Robson J, McHugh NJ, Herrick AL, Matucci-Cerinic M, Khanna D, Hewlett S.

Arthritis Care Res (Hoboken). 2017 Nov 21. doi: 10.1002/acr.23475. [Epub ahead of print]

PMID:
29473715
15.

Screening High-Resolution Computed Tomography of the Chest to Detect Interstitial Lung Disease in Systemic Sclerosis: A Global Survey of Rheumatologists.

Bernstein EJ, Khanna D, Lederer DJ.

Arthritis Rheumatol. 2018 Jun;70(6):971-972. doi: 10.1002/art.40441. Epub 2018 Apr 24. No abstract available.

PMID:
29426066
16.

Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis.

Distler O, Allanore Y, Denton CP, Matucci-Cerinic M, Pope JE, Hinzmann B, Davies S, de Oliveira Pena J, Khanna D.

Rheumatology (Oxford). 2018 May 1;57(5):813-817. doi: 10.1093/rheumatology/kex504.

17.

Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database.

Morgan ND, Shah AA, Mayes MD, Domsic RT, Medsger TA Jr, Steen VD, Varga J, Carns M, Ramos PS, Silver RM, Schiopu E, Khanna D, Hsu V, Gordon JK, Gladue H, Saketkoo LA, Criswell LA, Derk CT, Trojanowski MA, Shanmugam VK, Chung L, Valenzuela A, Jan R, Goldberg A, Remmers EF, Kastner DL, Wigley FM, Gourh P, Boin F.

Medicine (Baltimore). 2017 Dec;96(51):e8980. doi: 10.1097/MD.0000000000008980.

18.

Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study.

Murphy SL, Barber M, Homer K, Dodge C, Cutter G, Khanna D.

Arthritis Care Res (Hoboken). 2018 Jan 30. doi: 10.1002/acr.23522. [Epub ahead of print]

PMID:
29381834
19.

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE; SCOT Study Investigators.

N Engl J Med. 2018 Jan 4;378(1):35-47.

20.

Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations.

Gorlova OY, Li Y, Gorlov I, Ying J, Chen WV, Assassi S, Reveille JD, Arnett FC, Zhou X, Bossini-Castillo L, Lopez-Isac E, Acosta-Herrera M, Gregersen PK, Lee AT, Steen VD, Fessler BJ, Khanna D, Schiopu E, Silver RM, Molitor JA, Furst DE, Kafaja S, Simms RW, Lafyatis RA, Carreira P, Simeon CP, Castellvi I, Beltran E, Ortego N, Amos CI, Martin J, Mayes MD.

PLoS One. 2018 Jan 2;13(1):e0189498. doi: 10.1371/journal.pone.0189498. eCollection 2018.

21.

Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Kafaja S, Clements PJ, Wilhalme H, Tseng CH, Furst DE, Kim GH, Goldin J, Volkmann ER, Roth MD, Tashkin DP, Khanna D.

Am J Respir Crit Care Med. 2017 Nov 3. doi: 10.1164/rccm.201709-1845OC. [Epub ahead of print]

PMID:
29099620
22.

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Arnold MB, Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE, Pope JE.

Rheumatology (Oxford). 2018 Jan 1;57(1):152-157. doi: 10.1093/rheumatology/kex396.

PMID:
29077900
23.

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE.

Ann Rheum Dis. 2018 Feb;77(2):212-220. doi: 10.1136/annrheumdis-2017-211682. Epub 2017 Oct 24.

24.

Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.

Mihai C, Antic M, Dobrota R, Bonderman D, Chadha-Boreham H, Coghlan JG, Denton CP, Doelberg M, Grünig E, Khanna D, McLaughlin VV, Müller-Ladner U, Pope JE, Rosenberg DM, Seibold JR, Vonk MC, Distler O.

Ann Rheum Dis. 2018 Jan;77(1):128-132. doi: 10.1136/annrheumdis-2017-211480. Epub 2017 Oct 23.

PMID:
29061853
25.

Interstitial lung disease points to consider for clinical trials in systemic sclerosis.

Khanna D, Seibold J, Goldin J, Tashkin DP, Furst DE, Wells A.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v27-v32. doi: 10.1093/rheumatology/kex203. Review.

PMID:
28992174
26.

Assessment of skin involvement in systemic sclerosis.

Kumánovics G, Péntek M, Bae S, Opris D, Khanna D, Furst DE, Czirják L.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v53-v66. doi: 10.1093/rheumatology/kex202. Review.

PMID:
28992173
27.

Points to consider in renal involvement in systemic sclerosis.

Galluccio F, Müller-Ladner U, Furst DE, Khanna D, Matucci-Cerinic M.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v49-v52. doi: 10.1093/rheumatology/kex201. Review.

PMID:
28992172
28.

Points to consider for skin ulcers in systemic sclerosis.

Galluccio F, Allanore Y, Czirjak L, Furst DE, Khanna D, Matucci-Cerinic M.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v67-v71. doi: 10.1093/rheumatology/kex200. Review.

PMID:
28992171
29.

Points to consider-Raynaud's phenomenon in systemic sclerosis.

Cutolo M, Smith V, Furst DE, Khanna D, Herrick AL.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v45-v48. doi: 10.1093/rheumatology/kex199. Review.

PMID:
28992170
30.

Points to consider when doing a trial primarily involving the heart.

Allanore Y, Distler O, Walker UA, Khanna D, Furst DE, Meune C.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v12-v16. doi: 10.1093/rheumatology/kex198. Review.

PMID:
28992169
31.

Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.

Humbert M, Singh M, Furst DE, Khanna D, Seibold JR.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v33-v37. doi: 10.1093/rheumatology/kex197. Review.

PMID:
28992168
32.

Muscle involvement in systemic sclerosis: points to consider in clinical trials.

Walker UA, Clements PJ, Allanore Y, Distler O, Oddis CV, Khanna D, Furst DE.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v38-v44. doi: 10.1093/rheumatology/kex196. Review.

PMID:
28992167
33.

Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis.

Furst DE, Braun-Moscovic Y, Khanna D.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v4-v11. doi: 10.1093/rheumatology/kex195. Review.

PMID:
28992166
34.

Points to consider for designing trials in systemic sclerosis patients with arthritic involvement.

Clements P, Allanore Y, Furst DE, Khanna D.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v23-v26. doi: 10.1093/rheumatology/kex194. Review.

PMID:
28992165
35.

Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis.

Khanna D, Hays RD, Furst DE.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v17-v22. doi: 10.1093/rheumatology/kex193. Review.

PMID:
28992164
36.

There is a need for new systemic sclerosis subset criteria. A content analytic approach.

Johnson SR, Soowamber ML, Fransen J, Khanna D, Van Den Hoogen F, Baron M, Matucci-Cerinic M, Denton CP, Medsger TA Jr, Carreira PE, Riemekasten G, Distler J, Gabrielli A, Steen V, Chung L, Silver R, Varga J, Müller-Ladner U, Vonk MC, Walker UA, Wollheim FA, Herrick A, Furst DE, Czirjak L, Kowal-Bielecka O, Del Galdo F, Cutolo M, Hunzelmann N, Murray CD, Foeldvari I, Mouthon L, Damjanov N, Kahaleh B, Frech T, Assassi S, Saketkoo LA, Pope JE.

Scand J Rheumatol. 2018 Jan;47(1):62-70. doi: 10.1080/03009742.2017.1299793. Epub 2017 Oct 9.

PMID:
28990485
37.

Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases.

Nagaraja V, Mara C, Khanna PP, Namas R, Young A, Fox DA, Laing T, McCune WJ, Dodge C, Rizzo D, Almackenzie M, Khanna D.

Qual Life Res. 2018 Mar;27(3):755-764. doi: 10.1007/s11136-017-1709-z. Epub 2017 Oct 5.

PMID:
28983738
38.

Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta.

McCoy SS, Reed TJ, Berthier CC, Tsou PS, Liu J, Gudjonsson JE, Khanna D, Kahlenberg JM.

Rheumatology (Oxford). 2017 Nov 1;56(11):1970-1981. doi: 10.1093/rheumatology/kex280.

PMID:
28968684
39.

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Adler S, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F.

Arthritis Rheumatol. 2017 Sep;69(9):1903-1913. doi: 10.1002/art.40159. Epub 2017 Aug 4.

40.

Health care utilization in patients with gout: a prospective multicenter cohort study.

Singh JA, Bharat A, Khanna D, Aquino-Beaton C, Persselin JE, Duffy E, Elashoff D, Khanna PP.

BMC Musculoskelet Disord. 2017 May 31;18(1):233. doi: 10.1186/s12891-017-1573-6.

41.

Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.

Namas R, Tashkin DP, Furst DE, Wilhalme H, Tseng CH, Roth MD, Kafaja S, Volkmann E, Clements PJ, Khanna D; Participants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group.

Arthritis Care Res (Hoboken). 2018 Mar;70(3):439-444. doi: 10.1002/acr.23282. Epub 2018 Feb 9.

PMID:
28544580
42.

Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, Mayes M, Medsger T Jr, Merkel PA, Pope JE, Seibold JR, Steen V, Stevens W, Denton CP.

J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231.

43.

Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study.

Kwakkenbos L, Thombs BD, Khanna D, Carrier ME, Baron M, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mayes MD, Mouthon L, Nielson WR, Poiraudeau S, Riggs R, Sauvé M, Wigley F, Hudson M, Bartlett SJ; SPIN Investigators.

Rheumatology (Oxford). 2017 Aug 1;56(8):1302-1311. doi: 10.1093/rheumatology/kex055.

44.

Systemic sclerosis.

Denton CP, Khanna D.

Lancet. 2017 Oct 7;390(10103):1685-1699. doi: 10.1016/S0140-6736(17)30933-9. Epub 2017 Apr 13. Review.

PMID:
28413064
45.

Structural Validity of the Rheumatology Attitudes Index in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study.

Gholizadeh S, Mills SD, Fox RS, Merz EL, Roesch SC, Clements PJ, Kafaja S, Furst DE, Khanna D, Malcarne VL.

J Rheumatol. 2017 Jun;44(6):795-798. doi: 10.3899/jrheum.161080. Epub 2017 Apr 15.

46.

Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.

Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM.

Arthritis Rheumatol. 2017 Jul;69(7):1451-1460. doi: 10.1002/art.40114. Epub 2017 May 23.

47.

Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort.

Gordon JK, Girish G, Berrocal VJ, Zhang M, Hatzis C, Assassi S, Bernstein EJ, Domsic RT, Hant FN, Hinchcliff M, Schiopu E, Steen VD, Frech TM, Khanna D.

J Rheumatol. 2017 Jun;44(6):791-794. doi: 10.3899/jrheum.160654. Epub 2017 Mar 15.

48.

Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma.

Hutchings KM, Lisabeth EM, Rajeswaran W, Wilson MW, Sorenson RJ, Campbell PL, Ruth JH, Amin A, Tsou PS, Leipprandt JR, Olson SR, Wen B, Zhao T, Sun D, Khanna D, Fox DA, Neubig RR, Larsen SD.

Bioorg Med Chem Lett. 2017 Apr 15;27(8):1744-1749. doi: 10.1016/j.bmcl.2017.02.070. Epub 2017 Mar 10.

49.

Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales.

Khanna D, Hays RD, Shreiner AB, Melmed GY, Chang L, Khanna PP, Bolus R, Whitman C, Paz SH, Hays T, Reise SP, Spiegel B.

Dig Dis Sci. 2017 May;62(5):1186-1192. doi: 10.1007/s10620-017-4499-9. Epub 2017 Mar 1.

50.

Multiple Recession Coverage Using Pericardium Membrane.

Divakaran R, Khanna D, Babrawala I, George JP.

N Y State Dent J. 2017 Mar;83(2):52-5.

PMID:
29920035

Supplemental Content

Loading ...
Support Center